Clinical Trial Update: Phase II Trial GA101 Inbrutinib B CLL [Phase 2]

View source ↗

Summary

Phase II trial GA101 (obinutuzumab) in combination with ibrutinib for chronic lymphocytic leukemia has completed. The study was sponsored by the French Innovati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Status: COMPLETED